SWN
60
-6
HOG
29
-4
ZION
48
-2
NDAQ
46
-2
BXP
36
-8
URBN
50
-10
GE
60
-2
GILD
30
-7
KHC
40
2
NRG
74
-5
EFX
61
-5
NFLX
65
-3
MUR
50
-3
D
41
-5
FRT
41
-4
HAL
55
-7
TRIP
49
-9
OMC
55
11
GRMN
56
-3
ILMN
33
-9
SWN
60
-6
HOG
29
-4
ZION
48
-2
NDAQ
46
-2
BXP
36
-8
URBN
50
-10
GE
60
-2
GILD
30
-7
KHC
40
2
NRG
74
-5
EFX
61
-5
NFLX
65
-3
MUR
50
-3
D
41
-5
FRT
41
-4
HAL
55
-7
TRIP
49
-9
OMC
55
11
GRMN
56
-3
ILMN
33
-9
Financhill
Back

Amphastar Pharmaceuticals 10K Form

Sell
40

AMPH
Amphastar Pharmaceuticals

Last Price:
41.28
Seasonality Move:
14.88%

7 Day Trial

ALL ACCESS PASS

$ 7

Key Filings

10K form not available

Receive AMPH News And Ratings

See the #1 stock for the next 7 days that we like better than AMPH

AMPH Financial Statistics

Sales & Book Value

Annual Sales: $644.4M
Cash Flow: $14.42M
Price / Cash Flow: 14.87
Annual Sales: $13.30
Price / Book: 3.07

Profitability

EPS (TTM): 2.58000
Net Income (TTM): $137.55M
Gross Margin: $351.12M
Return on Equity: 23.71%
Return on Assets: 11.56%

Amphastar Pharmaceuticals Earnings Forecast

Key Amphastar Pharmaceuticals Financial Ratios

  • The Gross Profit Margin over the past 21 years for AMPH is 54.49%.
  • The Selling, General & Administrative Expenses for AMPH have been equal to 12.48% of Gross Profit Margin.
  • The Research & Development expenses have been 11.44% of Revenue.
  • The Interest Expense is 19.74% of Operating Income.
  • The Net Earning history of AMPH is 21.34% of Total Revenues.
  • Per Share Earnings over the last 21 years have been positive in 10 years.

Amphastar Pharmaceuticals Stock Price Chart

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Current Symbol: AMPH
CUSIP: 03209R
Website: amphastar.com

Debt

Debt-to-Equity Ratio: 0.92
Current Ratio: 2.17
Quick Ratio: 1.65

Price-to-Earnings

Trailing P/E Ratio: 15.68
Forward P/E Ratio: 9.59

AMPH Technical Analysis vs Fundamental Analysis

Sell
40
Amphastar Pharmaceuticals (AMPH) is a Sell

Is Amphastar Pharmaceuticals a Buy or a Sell?